Real-world data on semaglutide weight loss in 35,000 adults

NCT ID NCT07627074

Recruiting now Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study examines weight loss in adults who took semaglutide (a prescription weight management drug) as part of their routine care. Researchers will analyze medical records from about 35,000 people with overweight or obesity to see how much weight they lost and whether they achieved meaningful reductions. The goal is to understand how effective semaglutide is outside of controlled clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: semaglutide
What this could lead to: If successful, this study could confirm how well semaglutide works for weight loss in everyday settings, supporting its use for obesity management.
What could go wrong: This is an observational study, not a controlled trial, so results may be influenced by factors like patient selection or adherence. It cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Novo Nordisk Investigational Site
RECRUITING

Seattle, Washington, 98039, United States
Novo Nordisk Investigational Site
RECRUITING

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.